This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74:2913–21.
Levine AJ. Exploring the future of research in the Tp53 field. Cell Death Differ. 2022;29:893–4.
Barnett AH, Pyke DA. The genetics of diabetic complications. Clin Endocrinol Metab. 1986;15:715–26.
Butera A, Roy M, Zampieri C, Mammarella E, Panatta E, Melino G, et al. p53-driven lipidome influences non-cell-autonomous lysophospholipids in pancreatic cancer. Biol Direct. 2022;17:6.
Blandino G. Drugging THE MASTER REGulator TP53 in cancer: mission possible? J Clin Oncol. 2021;39:1595–7.
Sinn M, Sinn BV, Treue D, Keilholz U, Damm F, Schmuck R, et al. TP53 mutations predict sensitivity to adjuvant gemcitabine in patients with pancreatic ductal adenocarcinoma: next-generation sequencing results from the CONKO-001 Trial. Clin Cancer Res. 2020;26:3732–9.
Panatta E, Zampieri C, Melino G, Amelio I. Understanding p53 tumour suppressor network. Biol Direct. 2021;16:14.
Thomas AF, Kelly GL, Strasser A. Of the many cellular responses activated by TP53, which ones are critical for tumour suppression? Cell Death Differ. 2022;29:961–71.
Mammarella E, Zampieri C, Panatta E, Melino G, Amelio I. NUAK2 and RCan2 participate in the p53 mutant pro-tumorigenic network. Biol Direct. 2021;16:11.
Voutsadakis IA. Mutations of p53 associated with pancreatic cancer and therapeutic implications. Ann Hepatobiliary Pancreat Surg. 2021;25:315–27.
Lee MS, Dennis C, Naqvi I, Dailey L, Lorzadeh A, Ye G, et al. Ornithine aminotransferase supports polyamine synthesis in pancreatic cancer. Nature. 2023;616:339–47.
Zheng S, Wang X, Liu H, Zhao D, Lin Q, Jiang Q, et al. iASPP suppression mediates terminal UPR and improves BRAF-inhibitor sensitivity of colon cancers. Cell Death Differ. 2023;30:327–40.
Miller P, Akama-Garren EH, Owen RP, Demetriou C, Carroll TM, Slee E, et al. p53 inhibitor iASPP is an unexpected suppressor of KRAS and inflammation driven pancreatic cancer. Cell Death Differ. 2023, in press.
Panatta E, Butera A, Celardo I, Leist M, Melino G, Amelio I. p53 regulates expression of nuclear envelope components in cancer cells. Biol Direct. 2022;17:38.
Adiseshaiah PP, Crist RM, Hook SS, McNeil SE. Nanomedicine strategies to overcome the pathophysiological barriers of pancreatic cancer. Nat Rev Clin Oncol. 2016;13:750–65.
Agostini M, Mancini M, Candi E. Long non-coding RNAs affecting cell metabolism in cancer. Biol Direct. 2022;17:26.
Aubrey BJ, Brennan MS, Diepstraten ST, Wang Z, Chang C, Herold MJ, et al. Loss of TRP53 reduces but does not overcome dependency of lymphoma cells on MCL-1. Cell Death Differ. 2022;29:1074–6.
Donzelli S, Cioce M, Sacconi A, Zanconato F, Daralioti T, Goeman F, et al. A PIK3CA-mutant breast cancer metastatic patient-derived organoid approach to evaluate alpelisib treatment for multiple secondary lesions. Mol Cancer. 2022;21:152.
Wang Z, Strasser A, Kelly GL. Should mutant TP53 be targeted for cancer therapy? Cell Death Differ. 2022;29:911–20.
Funding
This work has been supported by the MUR-PNRR M4C2I1.3 PE6 project PE00000019 Heal Italia (CUP: H83C22000550006) to GB.
Author information
Authors and Affiliations
Contributions
GB wrote the manuscript.
Corresponding author
Ethics declarations
Competing interests
The author declares no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Blandino, G. Activated KRAS, polyamines, iASPP and TME: a multiple liaison in pancreatic cancer. Cell Death Differ 30, 1615–1617 (2023). https://doi.org/10.1038/s41418-023-01169-2
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41418-023-01169-2